San Juan Oncology Associates | Farmington, NM

Research site

(Unclaimed)

Location

2325 East 30th Street, Farmington, New Mexico, United States of America

Site insights

Top conditions

Top treatments

Trastuzumab

Obinutuzumab

Atezolizumab

Pertuzumab

Dexamethasone

Paclitaxel

Carboplatin

Lenalidomide

Erlotinib

Docetaxel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 61 total trials

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MD...

Enrolling

Myelodysplastic Syndrome

Acute Myeloid Leukemia

Drug: SEA-CD70

Drug: azacitidine

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Drug: Palbociclib

Drug: Giredestrant

Locations recently updated

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant

Drug: Dexamethasone Mouth Rinse

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Enrolling

Non-Hodgkin Lymphoma

Drug: Mosunetuzumab (Cohorts A-C)

Drug: Mosunetuzumab (Cohorts D-E)

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

Drug: Tiragolumab

Drug: Durvalumab

Locations recently updated

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your b...

Enrolling

HER2 Positive Breast Neoplasms

HER2 Low Breast Neoplasms

Drug: tucatinib

Drug: disitamab vedotin

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 ye...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Ixazomib

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling

Non Small Cell Lung Cancer

Drug: Docetaxel

Biological: Telisotuzumab Vedotin

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study...

Enrolling

Advanced Non-Small Cell Lung Cancer

Drug: Cemiplimab

Drug: BNT116

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only

Solid Tumor

Graft Vs Host Disease

Drug: Ibrutinib

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irino...

Active, not recruiting

Metastatic Colorectal Cancer

Colorectal Cancer

Drug: Bevacizumab

Drug: Onvansertib

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting

mCRPC

Drug: Talazoparib with enzalutamide

Drug: Placebo with enzalutamide